{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:22:07Z","timestamp":1791206527563,"version":"4.1.0"},"reference-count":33,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2022.0093","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:27:25Z","timestamp":1652873245000},"source":"Crossref","is-referenced-by-count":8,"title":["The prevention and treatment of nausea and vomiting during tumor therapy"],"prefix":"10.3238","author":[{"given":"Franziska","family":"Jahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"W\u00f6rmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Freidank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Feyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"10.3238\/arztebl.m2022.0093_ref1","doi-asserted-by":"crossref","unstructured":"Jordan K, Aapro M, Kaasa S, et al.: European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol 2018; 29: 36–43.","DOI":"10.1093\/annonc\/mdx757"},{"key":"10.3238\/arztebl.m2022.0093_ref2","doi-asserted-by":"crossref","unstructured":"Jordan K, Jahn F, Aapro M: Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 2015; 26: 1081–90.","DOI":"10.1093\/annonc\/mdv138"},{"key":"10.3238\/arztebl.m2022.0093_ref3","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen -Langversion 1.3, 2020, AWMF Registernummer: 032\/054OL, www.leitlinienprogramm-onkologie.de\/leitlinien\/supportive-therapie\/ (last accessed on 16 December 2021)."},{"key":"10.3238\/arztebl.m2022.0093_ref4","doi-asserted-by":"crossref","unstructured":"Jordan K, Feyer P, H\u00f6ller U, Link H, W\u00f6rmann B, Jahn F: Clinical practice guideline: Supportive treatments for patients with cancer. Dtsch Arztebl Int 2017; 114: 481–7.","DOI":"10.3238\/arztebl.2017.0481"},{"key":"10.3238\/arztebl.m2022.0093_ref5","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Kris MG, Basch E, et al.: Antiemetics: ASCO Guideline Update. J Clin Oncol 2020; 38: 2782–97.","DOI":"10.1200\/JCO.20.01296"},{"key":"10.3238\/arztebl.m2022.0093_ref6","doi-asserted-by":"crossref","unstructured":"Jordan K, Chan A, Gralla RJ, et al.: 2016 Updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 2017; 25: 271–5.","DOI":"10.1007\/s00520-016-3332-x"},{"key":"10.3238\/arztebl.m2022.0093_ref7","unstructured":"National Compehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Antiemesis, Version 1.2021. www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. 2020 (last accessed on 16 December 2021)."},{"key":"10.3238\/arztebl.m2022.0093_ref8","doi-asserted-by":"crossref","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al.: 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27 (Suppl 5): v119–v33.","DOI":"10.1093\/annonc\/mdw270"},{"key":"10.3238\/arztebl.m2022.0093_ref9","doi-asserted-by":"crossref","unstructured":"Ruhlmann CH, Jahn F, Jordan K, et al.: 2016 updated MASCC\/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. Support Care Cancer 2017; 25: 309–16.","DOI":"10.1007\/s00520-016-3407-8"},{"key":"10.3238\/arztebl.m2022.0093_ref10","doi-asserted-by":"crossref","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, et al.: The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 2017; 28: 1260–7.","DOI":"10.1093\/annonc\/mdx100"},{"key":"10.3238\/arztebl.m2022.0093_ref11","doi-asserted-by":"crossref","unstructured":"Feyer PC, Maranzano E, Molassiotis A, et al.: Radiotherapy-induced nausea and vomiting (RINV): MASCC\/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 2011; 19 (Suppl 1): 5–14.","DOI":"10.1007\/s00520-010-0950-6"},{"key":"10.3238\/arztebl.m2022.0093_ref12","unstructured":"Jordan K, Jahn F, Feyer P, et al.: Antiemese bei medikament\u00f6ser Tumortherapie – onkopedia Leitlinie 2021. www.onkopedia.com\/de\/onkopedia\/guidelines\/antiemese-bei-medikamentoeser-tumortherapie\/@@guideline\/html\/index.html (last accessed on 16 December 2021)."},{"key":"10.3238\/arztebl.m2022.0093_ref13","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, et al.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112–9.","DOI":"10.1200\/JCO.2003.01.095"},{"key":"10.3238\/arztebl.m2022.0093_ref14","doi-asserted-by":"crossref","unstructured":"Navari RM, Qin R, Ruddy KJ, et al.: Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375: 134–42.","DOI":"10.1056\/NEJMoa1515725"},{"key":"10.3238\/arztebl.m2022.0093_ref15","doi-asserted-by":"crossref","unstructured":"Albany C, Brames MJ, Fausel C, et al.: Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 2012; 30: 3998–4003.","DOI":"10.1200\/JCO.2011.39.5558"},{"key":"10.3238\/arztebl.m2022.0093_ref16","doi-asserted-by":"crossref","unstructured":"Schmitt T, Goldschmidt H, Neben K, et al.: Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 2014; 32: 3413–20.","DOI":"10.1200\/JCO.2013.55.0095"},{"key":"10.3238\/arztebl.m2022.0093_ref17","doi-asserted-by":"crossref","unstructured":"Clemmons AB, Orr J, Andrick B, et al.: Randomized, placebo-controlled, phase III trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) versus FOND Plus Olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: The FOND-O Trial. Biol Blood Marrow Transplant 2018; 24: 2065–71.","DOI":"10.1016\/j.bbmt.2018.06.005"},{"key":"10.3238\/arztebl.m2022.0093_ref18","doi-asserted-by":"crossref","unstructured":"Ruhlmann CH, Christensen TB, Dohn LH, et al.: Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 2016; 17: 509–18.","DOI":"10.1016\/S1470-2045(15)00615-4"},{"key":"10.3238\/arztebl.m2022.0093_ref19","unstructured":"Wong RK, Paul N, Ding K, et al.: 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006; 24: 3458–64."},{"key":"10.3238\/arztebl.m2022.0093_ref20","doi-asserted-by":"crossref","unstructured":"Roscoe JA, Morrow GR, Aapro MS, et al.: Anticipatory nausea and vomiting. Support Care Cancer. 2011; 19: 1533–8.","DOI":"10.1007\/s00520-010-0980-0"},{"key":"10.3238\/arztebl.m2022.0093_ref21","unstructured":"Jordan K, Jahn F, Feyer P, et al.: Antiemese bei medikament\u00f6ser Tumortherapie – onkopedia Leitlinie. In. 2019. ww.onkopedia.com\/de\/onkopedia\/guidelines\/antiemese-bei-medikamentoeser-tumortherapie\/@@guideline\/html\/index.html (last accessed on 1 Dezember 2021)."},{"key":"10.3238\/arztebl.m2022.0093_ref22","doi-asserted-by":"crossref","unstructured":"Saito M, Aogi K, Sekine I, et al.: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115–24.","DOI":"10.1016\/S1470-2045(08)70313-9"},{"key":"10.3238\/arztebl.m2022.0093_ref23","doi-asserted-by":"crossref","unstructured":"Aapro MS, Walko CM: Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010; 21: 2316–23.","DOI":"10.1093\/annonc\/mdq149"},{"key":"10.3238\/arztebl.m2022.0093_ref24","doi-asserted-by":"crossref","unstructured":"Natale JJ, Spinelli T, Calcagnile S, et al.: Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: review of clinical data. J Oncol Pharm Pract 2016; 22: 485–95.","DOI":"10.1177\/1078155215586824"},{"key":"10.3238\/arztebl.m2022.0093_ref25","doi-asserted-by":"crossref","unstructured":"Vardy J, Chiew KS, Galica J, et al.: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94: 1011–5.","DOI":"10.1038\/sj.bjc.6603048"},{"key":"10.3238\/arztebl.m2022.0093_ref26","unstructured":"EMA: Die Europ\u00e4ische Arzneimittel-Agentur empfiehlt \u00c4nderungen f\u00fcr die Anwendung von Metoclopramid. In. London, UK: European Medicines Agency 2013."},{"key":"10.3238\/arztebl.m2022.0093_ref27","unstructured":"Horneber M, Landwehr C, Kalbermatten-Magaya N, et al.: Medizinischer Cannabis und Cannabinoide – Onkopedia Leitlinie, URL: www.onkopedia.com\/de\/onkopedia\/guidelines\/medizinischer-cannabis-und-cannabinoide\/@@guideline\/html\/index.html. (last accessed on 16 December 2021)."},{"key":"10.3238\/arztebl.m2022.0093_ref28","doi-asserted-by":"crossref","unstructured":"Chow R, Valdez C, Chow N, et al.: Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. Support Care Cancer 2020; 28: 2095–103.","DOI":"10.1007\/s00520-019-05280-4"},{"key":"10.3238\/arztebl.m2022.0093_ref29","doi-asserted-by":"crossref","unstructured":"Grimison P, Mersiades A, Kirby A, et al.: Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 2020; 31: 1553–60.","DOI":"10.1016\/j.annonc.2020.07.020"},{"key":"10.3238\/arztebl.m2022.0093_ref30","doi-asserted-by":"crossref","unstructured":"Miao J, Liu X, Wu C, et al.: Effects of acupressure on chemotherapy-induced nausea and vomiting-a systematic review with meta-analyses and trial sequential analysis of randomized controlled trials. Int J Nurs Stud 2017; 70: 27–37.","DOI":"10.1016\/j.ijnurstu.2017.02.014"},{"key":"10.3238\/arztebl.m2022.0093_ref31","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Komplement\u00e4rmedizin in der Behandlung von onkologischen PatientInnen, Langversion 1.01 -Konsultationsfassung, 2020, AWMF Registernummer: 032\/055OL, www.leitlinienprogramm-onkologie.de\/leitlinien\/komplementaermedizi. 2020 (last accessed on 16 December 2021)."},{"key":"10.3238\/arztebl.m2022.0093_ref32","doi-asserted-by":"crossref","unstructured":"Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482–94.","DOI":"10.1056\/NEJMra0706547"},{"key":"10.3238\/arztebl.m2022.0093_ref33","doi-asserted-by":"crossref","unstructured":"Hu Z, Zhang L, Ma Y, et al.: Fruitful steps in the prevention of chemotherapy-induced nausea and vomiting (CINV) over the past 30 years: a historical comparison of patients enrolled in clinical trials during different antiemetic times. J Clin Oncol 2014; 32: e20685.","DOI":"10.1200\/jco.2014.32.15_suppl.e20685"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:28:07Z","timestamp":1652873287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2022.0093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":33,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2022.0093","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}